WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission (“SEC”), highlighting improved operational efficiency.
Related Questions
What potential impact could these results have on TVGN's stock price volatility and trading volume in the near term?
What are the primary factors driving the reduced expenses and are they sustainable moving forward?
How does the stronger second quarter performance compare to the company's guidance and analysts' expectations for the full year?